Statement of purpose
Cromeaux Inc. aims to become the largest provider of high quality clones within the Federation. The cloning business is becoming one of the most lucrative industries in the world of EVE and an innovative and vigorous company can quickly get a good turnover. Cromeaux Inc. has in recent months hired some of the best scientists in the field and intends with their help to develop further its pioneering cloning-technique to gain a sizeable market-share within the next five years. Cromeaux Inc. was founded 7 years ago as an independent division of the Chemal Tech, which owns 2/3 of the company. The rest is held by key employees (25%) and the Bank of Luminaire (8%). The funds raised in this round of finances will allow the company to grow to the level where it can start offering competitive products on a Federation-wide bases.
Business
Clones are a luxury commodity in high demand. The number of illegal clone clinics, often using inferior and even dangerous materials, clearly indicates that a substantial market is out there ready to be serviced by high quality, reliable and governmentally approved clones.
Cromeaux Inc. was founded 7 years ago by Dr. Yomir Veschens, an established expert in biochemistry and the entrepreneur Eron Jascete. Today it has more than 4.000 employees, including many of the leading geneticists and bioengineers in the world. Some of the key personnel currently employed by Cromeaux Inc. are:
- Dr. Yomir Veschens. CTO. Graduated from SWS in ’74 EST with a Ph.D. in both Biochemistry and Gene-design. Member of Dr. Jurg Akrael’s team and contributed to its successes in perfecting the brain mapping technique. Co-founder of Cromeaux Inc.
- Marika Alois. CEO. A respected manager, Alois has been director of several startup companies, including KS Manufacturing and DioSec. Became CEO of Cromeaux Inc. earlier this year.
- Daphnie Fonterouche. CFO. Former bank manager for Bank of Luminaire. Worked as an independent financial advisor before joining Cromeaux Inc. four years ago.
- Dr. Roul Gonzi. Senior Engineer. Former employee in the clone department of Poteque Pharmaceuticals, where he supervised the clone research team.
- Dr. Araham Keredin. Researcher. Dr. Keredin was a Biology professor at the Royal Institute on Amarr Prime before joining Cromeaux Inc. in the spring. He is an expert on mnemonic theories and psyche restoration.
Cromeaux Inc. already operates five cloning facilities in the Federation, all in high density, high yield areas. The company plans to open seven more facilities in the coming months, thereof four located on space stations. This is to tap into the clone demand from space ship captains, which are quickly becoming the largest group of clientele.
The largest manufacturer of clones within the Federation at the moment is Poteque Pharmaceuticals. Being the largest biotech company within the Federation Poteque made an easy transaction into the clone business as soon as the technology became financially viable and the laws for their use firm. However, the fact that the clone production is only a small subsection of the huge conglomerate means it is not a priority. Cromeaux Inc., on the other hand, by focusing solely on clones, have a unique opportunity to become a leader in the field of clone manufacturing.
Here is the current market breakdown between the largest clone companies:
- Poteque Pharmaceuticals [30%]
- Zainou [21%]
- Genolution [9%]
- Lai Dai [7%]
- Eifyr & Co. [4%]
- Cromeaux Inc. [1%]
- Other [28%]
